Wandercraft SAS broadened its U.S. FDA clearance for the Atalante X to include rehabilitation in individuals with spinal cord injuries at levels T5 to L5. The self-balancing exoskeleton was already given the greenlight by the FDA for use in stroke rehabilitation in December 2022. “We are thrilled to have two FDA clearances, first for stroke and now spinal cord injury, in less than a year,” CEO Matthieu Masselin, told BioWorld.

Rewalk Robotics Ltd. has integrated advanced sensing technologies and artificial intelligence (AI) into its latest exoskeleton prototype to enable autonomous decisionmaking. This milestone, coupled with Rewalk’s capabilities, holds enormous potential to create a new generation of exoskeletons that are more intuitive and respond to real-world conditions that users encounter daily, Rewalk CEO Larry Jasinski told BioWorld.

Wandercraft SAS has begun commercial operations of its exoskeleton, Atalante X, in the U.S., offering another solution to the millions of people living with mobility impairments. The company also formed a partnership with the Kessler Foundation whose research team will investigate the possible benefits of the Atalante X for neurologically impaired patients, including those recovering from stroke, spinal cord injuries and motor neuron disease.